Characterization of oral swab samples for diagnosis of pulmonary tuberculosis.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 09 09 2020
accepted: 26 04 2021
entrez: 17 5 2021
pubmed: 18 5 2021
medline: 21 10 2021
Statut: epublish

Résumé

Oral swab analysis (OSA) has been shown to detect Mycobacterium tuberculosis (MTB) DNA in patients with pulmonary tuberculosis (TB). In previous analyses, qPCR testing of swab samples collected from tongue dorsa was up to 93% sensitive relative to sputum GeneXpert, when 2 swabs per patient were tested. The present study modified sample collection methods to increase sample biomass and characterized the viability of bacilli present in tongue swabs. A qPCR targeting conserved bacterial ribosomal rRNA gene (rDNA) sequences was used to quantify bacterial biomass in samples. There was no detectable reduction in total bacterial rDNA signal over the course of 10 rapidly repeated tongue samplings, indicating that swabs collect only a small portion of the biomass available for testing. Copan FLOQSwabs collected ~2-fold more biomass than Puritan PurFlock swabs, the best brand used previously (p = 0.006). FLOQSwabs were therefore evaluated in patients with possible TB in Uganda. A FLOQSwab was collected from each patient upon enrollment (Day 1) and, in a subset of sputum GeneXpert Ultra-positive patients, a second swab was collected on the following day (Day 2). Swabs were tested for MTB DNA by manual IS6110-targeted qPCR. Relative to sputum GeneXpert Ultra, single-swab sensitivity was 88% (44/50) on Day 1 and 94.4% (17/18) on Day 2. Specificity was 79.2% (42/53). Among an expanded sample of Ugandan patients, 62% (87/141) had colony-forming bacilli in their tongue dorsum swab samples. These findings will help guide further development of this promising TB screening method.

Identifiants

pubmed: 33999938
doi: 10.1371/journal.pone.0251422
pii: PONE-D-20-28429
pmc: PMC8128230
doi:

Substances chimiques

DNA, Ribosomal 0
RNA, Bacterial 0
RNA, Ribosomal 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0251422

Subventions

Organisme : Bill & Melinda Gates Foundation
ID : INV-004527
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI139254
Pays : United States

Déclaration de conflit d'intérêts

At the time of study design and evaluation SB, CMB, DB, and AS received salary support from the Global Good Fund. At the time of study design and evaluation GH, KPN, AML, CO, DM, and KJM were employed by Intellectual Ventures Laboratory. There are no patents, products in development or marketed products to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials. A number of the authors are currently affiliated with GH Labs and Roche Molecular Systems, but were not affiliated with them during the study, and these companies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Références

Diagn Microbiol Infect Dis. 2020 Jan;96(1):114892
pubmed: 31727376
J Clin Microbiol. 2019 Feb 27;57(3):
pubmed: 30541931
PLoS One. 2019 Mar 26;14(3):e0214161
pubmed: 30913250
J Microbiol Methods. 2015 Jun;113:50-6
pubmed: 25863142
Sci Rep. 2019 Jul 25;9(1):10789
pubmed: 31346252
PLoS One. 2020 Oct 30;15(10):e0241542
pubmed: 33125422
Am J Trop Med Hyg. 2018 Mar;98(3):650-652
pubmed: 29363452
N Engl J Med. 2020 Jul 30;383(5):494-496
pubmed: 32492294
J Infect Dis. 2019 Oct 8;220(220 Suppl 3):S116-S125
pubmed: 31593600
BMC Res Notes. 2019 Jun 20;12(1):349
pubmed: 31221195
J Clin Med. 2020 Dec 21;9(12):
pubmed: 33371314
J Clin Microbiol. 2014 Jul;52(7):2493-9
pubmed: 24789182
Pediatr Infect Dis J. 2020 Nov;39(11):e376-e380
pubmed: 32675773
Clin Chem. 2015 Dec;61(12):1446-52
pubmed: 26510957
Sci Rep. 2015 Mar 02;5:8668
pubmed: 25727773

Auteurs

Rachel C Wood (RC)

Department of Environmental and Occupational Health Sciences, School of Public Health, University of Washington, Seattle, Washington, United States of America.

Alfred Andama (A)

Infectious Diseases Research Collaboration, Kampala, Uganda.
Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.

Gleda Hermansky (G)

Intellectual Ventures Laboratory, Bellevue, Washington, United States of America.

Stephen Burkot (S)

Intellectual Ventures' Global Good Fund, Bellevue, Washington, United States of America.

Lucy Asege (L)

Infectious Diseases Research Collaboration, Kampala, Uganda.

Mukwatamundu Job (M)

Infectious Diseases Research Collaboration, Kampala, Uganda.

David Katumba (D)

Infectious Diseases Research Collaboration, Kampala, Uganda.

Martha Nakaye (M)

Infectious Diseases Research Collaboration, Kampala, Uganda.

Sandra Z Mwebe (SZ)

Infectious Diseases Research Collaboration, Kampala, Uganda.

Jerry Mulondo (J)

Infectious Diseases Research Collaboration, Kampala, Uganda.

Christine M Bachman (CM)

Intellectual Ventures' Global Good Fund, Bellevue, Washington, United States of America.

Kevin P Nichols (KP)

Intellectual Ventures Laboratory, Bellevue, Washington, United States of America.

Anne-Laure M Le Ny (AM)

Intellectual Ventures Laboratory, Bellevue, Washington, United States of America.

Corrie Ortega (C)

Intellectual Ventures Laboratory, Bellevue, Washington, United States of America.

Rita N Olson (RN)

Department of Environmental and Occupational Health Sciences, School of Public Health, University of Washington, Seattle, Washington, United States of America.

Kris M Weigel (KM)

Department of Environmental and Occupational Health Sciences, School of Public Health, University of Washington, Seattle, Washington, United States of America.

Alaina M Olson (AM)

Department of Environmental and Occupational Health Sciences, School of Public Health, University of Washington, Seattle, Washington, United States of America.

Damian Madan (D)

Intellectual Ventures Laboratory, Bellevue, Washington, United States of America.

David Bell (D)

Intellectual Ventures' Global Good Fund, Bellevue, Washington, United States of America.

Adithya Cattamanchi (A)

Division of Pulmonary and Critical Care Medicine and Center for Tuberculosis, Zuckerberg San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.

William Worodria (W)

Infectious Diseases Research Collaboration, Kampala, Uganda.
Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.

Fred C Semitala (FC)

Infectious Diseases Research Collaboration, Kampala, Uganda.
Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.

Akos Somoskovi (A)

Intellectual Ventures' Global Good Fund, Bellevue, Washington, United States of America.

Gerard A Cangelosi (GA)

Department of Environmental and Occupational Health Sciences, School of Public Health, University of Washington, Seattle, Washington, United States of America.

Kyle J Minch (KJ)

Intellectual Ventures Laboratory, Bellevue, Washington, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH